Drug Trial Radar · NCT06678659
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
310
Planned (sponsor's estimate)
Start
Nov 21, 2024
Primary completion
Jul 2029
Study completion Jul 2029
Sponsor
- Lead sponsor
- Recursion Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 7, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label study to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary activity of REC-1245 administered orally on a once daily (QD) schedule in participants with unresectable, locally advanced, or metastatic solid tumors.
Conditions
- Unresectable
- Locally Advanced
- Metastatic Cancers
- Relapsed/Refractory Lymphomas
Interventions
REC-1245Drug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1-Part 1A (Dose Finding)- Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Initiation of study drug through 4 weeks
- Phase 1 and 2 - Number of Participants With a Treatment-emergent Adverse EventTime frame: Initiation of study drug through 30 days after the last dose (up to approximately 24 months)
- Phase 2- Objective Response Rate (ORR)Time frame: Initiation from study drug until disease progression (up to approximately 24 months)
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
City of Hope
Duarte, California · Recruiting
Stanford Women's Cancer Center
Palo Alto, California · Recruiting
Sarcoma Oncology Research Center
Santa Monica, California · Recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
SCRI Oncology Partners - PPDS
Nashville, Tennessee · Withdrawn
START Mountain Region
West Valley City, Utah · Recruiting
McGill University Health Centre (MUHC) - The Montreal
Québec, Canada · Recruiting
Princess Margaret Cancer Centre
Toronto, Ontario, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.